Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

17 July 2014

Ahead of the International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool has announced seven new sublicensing agreements for atazanavir and dolutegravir.

The United Nations-backed body has signed agreements with the USA’s Bristol Myers-Squib (NYSE: BMY), Gilead Sciences (Nasdaq: GILD), Swiss drug major Roche (ROG: SIX), the US National Institutes of Health and ViiV Healthcare (majority-owned by GlaxoSmithKline; LSE: GSK) for eight antiretrovirals and one medicine for an HIV opportunistic infection.

Greg Perry, executive director of the Medicines Patent Pool, said: "With licenses signed today, four new manufacturers are joining us to speed the availability of crucial medicines, ATV and DTG, to developing countries. This almost doubles our network of generic partners to ten companies. Increased generic competition will ultimately bring prices down and increase availability to allow national treatment programs to treat many more people in their countries."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK